Absci Reports Increased Losses and Revenue Decline, Secures $105.8M in Capital, Advances Lead Clinical Candidate ABS-201, and Details AMD Partnership

summarizeSummary

Absci Corp reported increased net losses and decreased revenue in its 2025 annual report, but secured $105.8 million in capital, initiated a Phase 1/2a clinical trial for its lead candidate ABS-201 with favorable early safety, and formed a strategic partnership with AMD.

check_boxKey Events

• Increased Net Loss and Revenue Decline

  Absci Corp reported a net loss of $115.2 million for the year ended December 31, 2025, an increase from $103.1 million in 2024. Partner program revenue decreased by 38% to $2.8 million in 2025 from $4.5 million in 2024.

• Significant Capital Raises in 2025

  The company secured $105.8 million in net proceeds from equity issuances in 2025, including a $20.0 million private investment in public equity (PIPE) from Advanced Micro Devices, Inc. (AMD) and a $46.7 million public offering. This funding is expected to provide liquidity for at least the next 12 months.

• Lead Candidate ABS-201 Advances to Clinic

  The Phase 1/2a HEADLINE clinical trial for ABS-201, targeting androgenetic alopecia, was initiated in December 2025. The first three single ascending dose cohorts have shown favorable emerging safety data, with interim proof-of-concept data expected in the second half of 2026. A Phase 2 trial for endometriosis is planned for Q4 2026.

• Strategic Collaboration with AMD

  In January 2025, Absci entered a strategic collaboration with AMD to optimize AMD Instinct accelerators and ROCm software for its AI drug creation, further validated by AMD's $20.0 million PIPE investment at a premium over market price.

auto_awesomeAnalysis

Absci Corp's annual report reveals a challenging financial year with increased net losses and a significant drop in revenue. However, the company successfully raised substantial capital through a PIPE investment from AMD and a public offering, which is critical for its liquidity and operations for at least the next 12 months. The initiation of the Phase 1/2a clinical trial for its lead candidate, ABS-201, with favorable early safety data, and the strategic collaboration with AMD, are key positive developments for a clinical-stage biotech. The decision to seek a partner for ABS-101, despite positive early results, indicates a strategic reprioritization of resources. Investors should monitor the progress of ABS-201's clinical trials and the company's ability to manage its cash burn and secure future funding without excessive dilution.